ELMD at a glance
Electromed, Inc. (ELMD, SEC CIK 1488917) filed its latest 10-K annual report on August 25, 2026, a 10-Q quarterly report on May 12, 2026, an 8-K current report on August 25, 2026 and Form 4 insider filings as recently as September 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended June 30, 2026 (FY2026), Electromed, Inc. (ELMD) reported revenue of $73.8 million (up 15.3% from FY2025) and net income of $11.3 million. Diluted EPS was $1.30.
- As of June 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Electromed, Inc. (ELMD) shares worth $82.4 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Cunniff James L. on June 8, 2026 of 7,003 shares at $36.25 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2026
- $73.8M
- +15.3% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 24 funds
- $82.4M · +2 vs prior quarter
- Latest 8-K
- Aug 25, 2026
- Item 7.01 · Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $73.8M, up 15.3% YoY driven by homecare growth: $66.6M (+16.3%), hospital $3.4M (+9.6%), distributor $3.3M (+12.7%)
- Gross margin 78.5% vs 78.1%; Operating income $13.9M (+43.7%) margin approx. 18.8% vs 15.1% in prior year
- Best segment: Homecare revenue $66.6M (+$9.3M); Worst: Other revenue $0.4M (-34.7%)
- Operating cash flow $9.7M; Capex $1.25M; Share repurchase $3.9M; Dividends not mentioned
- Fiscal 2027 risks: Supply chain constraints, inflationary component costs, geopolitical conflict; strategy to expand sales force and bronchiectasis market presence
Business Overview
- Core business model: Direct-to-patient and provider sales of SmartVest HFCWO airway clearance therapy systems, bypassing traditional HME channels
- New product introduction: SmartVest Clearway launched Nov 2022, featuring touchscreen interface, single-hose patented design, lighter <14 lb generator for enhanced patient experience
- Strategic emphasis shift: Increased focus on bronchiectasis market, growing 12% annually with underpenetrated ~16% therapy adoption in ~1 million diagnosed US patients
- Quantitative highlights: Fiscal 2026 revenue $73.4M US-based (95.3% homecare), 58 direct sales employees, R&D spend up to $1.31M (1.8% revenue), 197 employees total
- Noteworthy 2026 fact: Publication and presentation of recent 2023-2025 clinical studies validating HFCWO efficacy in bronchiectasis and COPD, underscoring under-prescription and growth opportunity
AI summary of the ELMD 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Mar 31, 2026
Risk Factors
- No quarterly risk-factor disclosure; smaller reporting company exemption
- No new regulatory, legal, operational, competitive, market, or financial risks identified
- Risk-factor section provides no updates versus the most recent 10-K
AI summary of the ELMD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Earnings announcement, investor presentation, and executive succession materials released August 25, 2026
- Investor presentation likely provides management’s operating outlook and strategic priorities
Item 2.02: Results of Operations and Financial Condition
- CEO James L. Cunniff plans retirement effective on or about April 2, 2027
- Expected Board resignation alongside CEO departure
Item 2.02: Results of Operations and Financial Condition
- Updated investor presentation furnished as Exhibit 99.2 under Regulation FD
- Presentation may contain fiscal 2026 operating or financial updates relevant to investors
AI summaries of ELMD 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ELMD
Don't miss the next ELMD filing
- Alerts as it files. A push when ELMD files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ELMD, by share count.
- Ask anything. An AI agent that reads every ELMD filing and answers with sources.
ELMD alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Cunniff James L. | F | Sep 1, 2026 | 2,671 | $27.10 |
| Nagel Bradley M. | F | Sep 1, 2026 | 1,102 | $27.10 |
| Nagel Bradley M. | A | Sep 1, 2026 | 4,900 | - |
| Nagel Bradley M. | A | Sep 1, 2026 | 9,600 | - |
| Nagel Bradley M. | F | Jun 30, 2026 | 674 | $42.30 |
| Cunniff James L. | Sell | Jun 8, 2026 | 7,003 | $36.25 |
| Cunniff James L. | Sell | Jun 8, 2026 | 1,026 | $37.77 |
| Cunniff James L. | Sell | Jun 8, 2026 | 1,671 | $36.80 |
Financial SummaryXBRL
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $64.0M | $73.8M |
| Gross Profit | - | $50.0M | $57.9M |
| Operating Income | - | $9.7M | $13.9M |
| Net Income | - | $7.5M | $11.3M |
| Gross Margin | - | 78.1% | 78.5% |
| Op. Margin | - | 15.1% | 18.8% |
| Net Margin | - | 11.8% | 15.3% |
| Balance Sheet | |||
| Total Assets | $52.2M | $53.8M | $66.3M |
| Equity | $44.5M | $43.2M | $54.0M |
| ROE | - | 17.4% | 20.9% |
| Per Share | |||
| EPS | - | $0.85 | $1.30 |
| Cash Flow | |||
| Operating CF | - | $11.4M | $9.7M |
| CapEx | - | $262K | $1.3M |
Source: XBRL data in Electromed, Inc. (ELMD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ELMD share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 24 | $82.4M |
| Q1 2026 | 22 | $44.9M |
| Q4 2025 | 21 | $58.0M |
| Q3 2025 | 20 | $51.4M |
| Q2 2025 | 20 | $42.6M |
| Q1 2025 | 19 | $34.6M |
| Q4 2024 | 14 | $31.4M |
| Q3 2024 | 10 | $12.1M |
- Citadel Advisors LLC+22.6K (+116%)
- AQR Capital Management+22.5K (+153%)
- Bank of America Corp+20.7K (+121%)
- BlackRock+6.8K (+1%)
- State Street Corp+6.3K (+6%)
- Vanguard Capital Management LLC−51.8K (-15%)
- Two Sigma Investments−36.1K (-18%)
- Renaissance Technologies LLC−24.3K (-20%)
- Northern Trust−8.2K (-9%)
- Ameriprise Financial−3.2K (-7%)
- Invesco Ltd+51.4K
- T. Rowe Price Group+4.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 150 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ELMD filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 8-K | Aug 25, 2026 | - | Analysis | - |
| 10-K | Aug 25, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | May 19, 2026 | - | - | |
| 8-K | May 12, 2026 | - | Analysis | |
| 10-Q | May 12, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Feb 10, 2026 | - | - | |
| 10-Q | Feb 10, 2026 | Dec 31, 2025 | Analysis | |
| 8-K | Dec 18, 2025 | - | - | |
| 4 | Dec 3, 2025 | - | - | |
| 4 | Dec 3, 2025 | - | - | |
| 4 | Dec 3, 2025 | - | - | |
| 4 | Dec 3, 2025 | - | - | |
| 4 | Dec 3, 2025 | - | - | |
| 4 | Dec 3, 2025 | - | - | |
| 4 | Dec 3, 2025 | - | - | |
| 10-Q | Nov 12, 2025 | Sep 30, 2025 | Analysis | |
| 10-K | Aug 26, 2025 | Jun 30, 2025 | - | |
| SC 13G | Jul 29, 2025 | - | - | |
| 10-Q | May 13, 2025 | Mar 31, 2025 | - | |
| 10-Q | Feb 11, 2025 | Dec 31, 2024 | - |
Related Health Care companies
- AXGN · Axogen, Inc.Electromedical & Electrotherapeutic Apparatus
- BLFS · BIOLIFE SOLUTIONS INCElectromedical & Electrotherapeutic Apparatus
- CV · CapsoVision, IncElectromedical & Electrotherapeutic Apparatus
- CBLL · Ceribell, Inc.Electromedical & Electrotherapeutic Apparatus
- CNMD · CONMED CorpElectromedical & Electrotherapeutic Apparatus
- HYPR · Hyperfine IncElectromedical & Electrotherapeutic Apparatus
- ITGR · Integer Holdings CorpElectromedical & Electrotherapeutic Apparatus
- LIVN · LivaNova PLCElectromedical & Electrotherapeutic Apparatus
ELMD SEC filings: frequently asked questions
Which institutions hold ELMD stock?
As of June 30, 2026, the largest Electromed, Inc. (ELMD) holders among the 13F filers tracked by SignalX were BlackRock ($19.7 million), Vanguard Capital Management LLC ($12.0 million), Dimensional Fund Advisors ($7.6 million), Two Sigma Investments ($7.1 million), State Street Corp ($4.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ELMD's revenue in fiscal year 2026?
For the fiscal year ended June 30, 2026 (FY2026), Electromed, Inc. (ELMD) reported revenue of $73.8 million (up 15.3% from FY2025) and net income of $11.3 million. Diluted EPS was $1.30. The figures come from the XBRL data in the 10-K.
What did ELMD report in its latest 8-K?
Electromed, Inc. (ELMD) filed an 8-K on August 25, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 2.02 (Results of Operations and Financial Condition). Earnings announcement, investor presentation, and executive succession materials released August 25, 2026.
What are the latest ELMD SEC filings?
Electromed, Inc. (ELMD) filed its latest 10-K annual report on August 25, 2026, a 10-Q quarterly report on May 12, 2026, an 8-K current report on August 25, 2026 and a Form 4 insider filing on September 3, 2026.
What is ELMD's SEC CIK number?
Electromed, Inc. (ELMD)'s SEC Central Index Key (CIK) is 1488917. EDGAR lists every ELMD filing under that number.
Ask anything about ELMD
The research agent reads ELMD's filings, financials, insider trades and 13F holders, then answers with sources.